{{noteTA|G1 = ME}}
{{Infobox medical condition (new)
| name            = 膽管癌
| synonyms        = 
| image           = Cholangiocarcinoma - very high mag.jpg
| width           = 
| alt             = 
| caption         = 肝內膽管癌（右側）和正常肝細胞（左側）的組織切片，[[HE染色|HE染色]]。
| pronounce       = 
| field           = [[肿瘤学|肿瘤学]]
| symptoms        = [[腹痛|腹痛]]、[[黄疸|黄疸]]、[[體重下降|體重下降]]、[[癢|全身搔癢]]、發燒<ref name=NCI2018Pro/>
| complications   =
| onset           = 約70歲<ref name=Lancet2014/>
| duration        =
| types           = 肝內型（Intrahepatic）、肝門型（perihilar）、遠端型（distal）<ref name=Lancet2014/>
| causes          =
| risks           = [[原發性硬化性膽管炎|原發性硬化性膽管炎]]、[[溃疡性结肠炎|溃疡性结肠炎]]、特定{{tsl|en|liver fluke|肝吸蟲}}感染、先天肝發育異常<ref name=NCI2018Pro/>
| diagnosis       = 顯微病理切片<ref name=NCI2018Sym/>
| differential    =
| prevention      =
| treatment       = {{tsl|en|Surgical resection|手術切除}}、[[化学疗法|化学疗法]]、[[放射線療法|放射線療法]]、膽道[[支架|支架]]、{{tsl|en|liver transplantation|肝臟移植}}<ref name=NCI2018Pro/>
| medication      =
| prognosis       = 通常很差<ref name=WCR2014_5.6/>
| frequency       = 約每年每10萬人1–2例（西方國家）<ref name=Brid2016/>
| deaths          = 
}}
{{医学警告}}
'''膽管癌'''（{{Lang|la|Cholangiocarcinoma}}），又稱'''膽道癌'''，是一種由[[膽管|膽道]][[上皮細胞|上皮細胞]]（或呈現上皮細胞分化特征的細胞）[[逆行性生長|癌变]]所造成的[[癌症|癌症]]<ref name=NCI2019Def>{{cite web |title=NCI Dictionary of Cancer Terms |url=https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cholangiocarcinoma |website=National Cancer Institute |accessdate=21 January 2019 |language=en |date=2 February 2011 |archive-date=2019-07-09 |archive-url=https://web.archive.org/web/20190709031747/https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cholangiocarcinoma |dead-url=no }}</ref>。膽管癌主要的症狀為[[肝功能測試|肝功能]]異常、[[腹痛|腹痛]]、[[黃疸|黃疸]]、全身搔癢、[[發燒|發燒]]和[[體重下降|體重減輕]]<ref name=NCI2018Pro>{{cite web |title=Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version |url=https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq#section/all |website=National Cancer Institute |accessdate=21 January 2019 |language=en |date=14 March 2018 |archive-date=2019-07-09 |archive-url=https://web.archive.org/web/20190709021307/https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq#section/all |dead-url=no }}</ref>；此外患者的[[糞便|糞便]]顏色可能變淺，[[尿液|尿液]]顏色變深<ref name=NCI2018Sym/>。同屬{{tsl|en|biliary tract|膽道系統}}癌症的疾病還包括[[膽囊癌|膽囊癌]]和{{tsl|en|ampulla of Vater|十二指腸乳頭癌}}<ref>{{cite journal |last1=Benavides |first1=M |last2=Antón |first2=A |last3=Gallego |first3=J |last4=Gómez |first4=MA |last5=Jiménez-Gordo |first5=A |last6=La Casta |first6=A |last7=Laquente |first7=B |last8=Macarulla |first8=T |last9=Rodríguez-Mowbray |first9=JR |last10=Maurel |first10=J |title=Biliary tract cancers: SEOM clinical guidelines. |journal=Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico |date=December 2015 |volume=17 |issue=12 |pages=982–7 |doi=10.1007/s12094-015-1436-2 |pmid=26607930}}</ref>。膽管癌是一種罕見的[[腺癌|腺癌]]<ref name=Lancet2014/>。

膽管癌的風險因子包含[[原發性硬化性膽管炎|原發性硬化性膽管炎]]、[[溃疡性结肠炎|溃疡性结肠炎]]、[[肝硬化|肝硬化]]、[[丙型肝炎|丙型肝炎]]、[[乙型肝炎|乙型肝炎]]、特定{{tsl|en|liver fluke|肝吸蟲}}感染，以及先天肝臟結構異常等等<ref name=NCI2018Pro/><ref name=Lancet2014/><ref>{{cite journal |last1=Steele |first1=JA |last2=Richter |first2=CH |last3=Echaubard |first3=P |last4=Saenna |first4=P |last5=Stout |first5=V |last6=Sithithaworn |first6=P |last7=Wilcox |first7=BA |title=Thinking beyond Opisthorchis viverrini for risk of cholangiocarcinoma in the lower Mekong region: a systematic review and meta-analysis. |journal=Infectious diseases of poverty |date=17 May 2018 |volume=7 |issue=1 |pages=44 |doi=10.1186/s40249-018-0434-3 |pmid=29769113}}</ref>。但大多數膽管癌患者缺乏明確的風險因子背景可供辨識<ref name=Lancet2014/>。疾病的診斷須結合[[血液检查|血液检查]]、[[醫學影像|醫學影像]]，和[[內視鏡|內視鏡]]检查，有時需手術取出檢體進行病理診斷<ref name=NCI2018Sym/>。確診須經由顯微鏡檢進行<ref name=NCI2018Sym>{{cite web |title=Bile Duct Cancer (Cholangiocarcinoma) Symptoms, Tests, Prognosis, and Stages |url=https://www.cancer.gov/types/liver/patient/about-bile-duct-cancer-pdq#section/all |website=National Cancer Institute |accessdate=21 January 2019 |language=en |date=5 July 2018 |archive-date=2019-07-08 |archive-url=https://web.archive.org/web/20190708223208/https://www.cancer.gov/types/liver/patient/about-bile-duct-cancer-pdq#section/all |dead-url=no }}</ref>。

多數患者在診斷出膽管癌時，疾病已經進展至晚期，無法治癒<ref name="NCI2018Pro" />。在這些無法治癒的病人可進行[[和缓医疗|和缓医疗]]，包含{{tsl|en|surgical resection|手術切除}}、[[化学疗法|化学疗法]]、[[放射線療法|放射線療法]]，以及置放膽道[[支架|支架]]等等<ref name="NCI2018Pro" />。完全手術切除是唯一的治癒希望，但有約三分之一的病人腫瘤會進犯{{tsl|en|common bile duct|總膽管}}，而此類腫瘤無法手術切除，因此僅有少數腫瘤可以進行完全切除<ref name="NCI2018Pro" />。完全切除後仍然建議繼續進行化療及放療<ref name="NCI2018Pro" />。有些符合特定條件的病人可以進行{{tsl|en|liver transplantation|肝臟移植}}<ref name="Lancet2014">{{cite journal |last1=Razumilava |first1=N |last2=Gores |first2=GJ |title=Cholangiocarcinoma. |journal=Lancet |date=21 June 2014 |volume=383 |issue=9935 |pages=2168–79 |doi=10.1016/S0140-6736(13)61903-0 |pmid=24581682}}</ref>，但術後的[[五年存活率|五年存活率]]仍不到五成<ref name="Brid2016" />。

膽管癌在[[西方世界|西方世界]]相當罕見，大約每年每10萬人僅 0.5–2 例<ref name="NCI2018Pro" /><ref name="Brid2016" />。[[东南亚|东南亚]]等肝吸蟲流行的地區發生率較高<ref name="WCR2014_5.6">{{cite book |last1=Bosman |first1=Frank T. |editor1-last=Stewart |editor1-first=Bernard W. |editor2-last=Wild |editor2-first=Christopher P |title=World Cancer Report |date=2014 |publisher=the International Agency for Research on Cancer, World Health Organization |isbn=978-92-832-0443-5 |pages=Chapter 5.6 |chapter-url=http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014 |chapter=Chapter Chapter 5.6: Liver cancer |access-date=2019-02-06 |archive-date=2016-09-19 |archive-url=https://web.archive.org/web/20160919073553/http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014 |dead-url=yes }} {{open access}}</ref>，如[[泰国|泰国]]約每年每10萬人60例<ref name="WCR2014_5.6" />。[[大韩民国|韓國]]、[[上海市|上海]]的發生率甚至高於罕見癌症的標準<ref name=":0" />。膽管癌一般發生於70歲左右，但患有原發性硬化性膽管炎者常在40歲左右即發病<ref name="Lancet2014" />。現今西方國家的肝內型膽管癌比例比起過去較高<ref name="Brid2016">{{cite journal |last1=Bridgewater |first1=JA |last2=Goodman |first2=KA |last3=Kalyan |first3=A |last4=Mulcahy |first4=MF |title=Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. |journal=American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting |date=2016 |volume=35 |pages=e194-203 |doi=10.1200/EDBK_160831 |pmid=27249723}}</ref>。

==症狀和症候群==
[[File:Jaundice_eye.jpg|thumb]]和鞏膜黄染）]]
膽管癌最常見的生理變化為[[肝功能測試|肝功能異常]]、[[黃疸|黃疸]]（膽管阻塞後，膽汁導致眼睛和皮膚變黃）、[[腹痛|腹痛]]（30%–50%）、全身搔癢（66%）、體重減輕（30%–50%）、[[發燒|發燒]]（小於20%）、糞便和尿液顏色改變<ref>{{cite journal |author=Nagorney D, Donohue J, Farnell M, Schleck C, Ilstrup D |title=Outcomes after curative resections of cholangiocarcinoma |journal=Arch Surg |volume=128 |issue=8 |pages=871–7; discussion 877–9 |year=1993 |pmid=8393652 |doi=10.1001/archsurg.1993.01420200045008}}</ref><ref>{{Cite web |url=http://www.surgery.usc.edu/divisions/tumor/pancreasdiseases/web%20pages/BILIARY%20SYSTEM/cholangiocarcinoma.html |title=Bile duct cancer: cause and treatment<!-- Bot generated title --> |accessdate=2016-06-04 |archive-date=2018-04-23 |archive-url=https://web.archive.org/web/20180423024014/http://www.surgery.usc.edu/divisions/tumor/pancreasdiseases/web%20pages/BILIARY%20SYSTEM/cholangiocarcinoma.html |dead-url=no }}</ref>。症狀的類別取決於腫瘤在膽管中的位置：位於肝外膽管者較可能發生黃疸；位在肝內膽者則較常發生腹痛，但不常伴隨黃疸<ref name="nakeeb">{{cite journal |vauthors=Nakeeb A, Pitt H, Sohn T, Coleman J, Abrams R, Piantadosi S, Hruban R, Lillemoe K, Yeo C, Cameron J |title=Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors |url=https://archive.org/details/sim_annals-of-surgery_1996-10_224_4/page/463 |journal=Ann Surg |volume=224 |issue=4 |pages=463–73; discussion 473–5 |year=1996 |pmid=8857851 |doi=10.1097/00000658-199610000-00005 |pmc=1235406}}</ref>。

膽管癌患者的[[肝功能測試|肝功能血液檢驗]]報告往往會呈現出各種「阻塞性」特徵：意即[[膽色素|膽色素]]、[[鹼性磷酸酶|鹼性磷酸酶]]、{{le|丙麩胺酸轉移酶|gamma glutamyl transferase}}濃度上升，但[[转氨酶|转氨酶]]濃度正常，此類檢驗結果排除了發炎或肝實質組織感染的可能，明確指出黃疸的病灶來自膽管阻塞<ref name="feldman2">{{cite book|editor1=Mark Feldman |editor2=Lawrence S. Friedman |editor3=Lawrence J. Brandt |title=Sleisenger and Fordtran's Gastrointestinal and Liver Disease|edition=8th|date=21 July 2006|publisher=Saunders|isbn=978-1-4160-0245-1|pages=1493–6}}</ref>。多數的膽管癌患者[[CA19-9|CA19-9]]濃度也會上升<ref>{{Cite journal|title=The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis|url=https://www.ncbi.nlm.nih.gov/pubmed/16133981|last=Levy|first=Cynthia|last2=Lymp|first2=James|date=2005-09-01|journal=Digestive Diseases and Sciences|issue=9|doi=10.1007/s10620-005-2927-8|volume=50|pages=1734–1740|issn=0163-2116|pmid=16133981|last3=Angulo|first3=Paul|last4=Gores|first4=Gregory J.|last5=Larusso|first5=Nicholas|last6=Lindor|first6=Keith D.|access-date=2016-07-27|archive-date=2019-07-07|archive-url=https://web.archive.org/web/20190707004125/https://www.ncbi.nlm.nih.gov/pubmed/16133981|dead-url=no}}</ref>。

==風險因子==
[[File:Clonorchis_sinensis_LifeCycle.png|thumb]]的生活史，以下說明與圖中數字一致：
(1) 受精卵透過糞便離開人體。
(2) 卵被蝸牛食入後，依序發育為毛蚴、孢蚴、雷蚴、尾蚴。
(3) 自由游動的尾蚴離開蝸牛，在淡水魚皮膚或肌肉內形成囊蚴。
(4) 淡水魚被人類食用後，囊蚴進入人體。
(5) 囊蚴在十二指腸破出囊孢。
(6) 成體寄生在膽管。
]]

雖然多數膽管癌患者形成腫瘤的原因並不明確，但目前已发现相当多的[[風險因子|風險因子]]。西方國家最常見的風險因子為[[原發性硬化性膽管炎|原發性硬化性膽管炎]]（PSC），這是一種和[[潰瘍性結腸炎|潰瘍性結腸炎]]高度相關的膽道發炎疾病<ref>{{cite journal |author=Chapman R |title=Risk factors for biliary tract carcinogenesis |journal=Ann Oncol |volume=10 |issue=Suppl 4 |pages=308–11 |year= 1999|pmid=10436847 |doi=10.1023/A:1008313809752}}</ref>，流行病學統計指出PSC患者一生中罹患膽管癌的機率為10%–15%<ref>下列為有關原發性硬化膽管炎及膽管癌的相關性研究：
* {{cite journal |vauthors=Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzén H, Almer S, Granath F, Broomé U |title=Hepatic and extrahepatic malignancies in primary sclerosing cholangitis |journal=J Hepatol |volume=36 |issue=3 |pages=321–7 |year=2002 |pmid=11867174 |doi=10.1016/S0168-8278(01)00288-4}}
* {{cite journal |vauthors=Bergquist A, Glaumann H, Persson B, Broomé U |title=Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study |journal=Hepatology |volume=27 |issue=2 |pages=311–6 |year=1998 |pmid=9462625 |doi=10.1002/hep.510270201}}
* {{cite journal |vauthors=Burak K, Angulo P, Pasha T, Egan K, Petz J, Lindor K |title=Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis |url=https://archive.org/details/sim_american-journal-of-gastroenterology_2004-03_99_3/page/523 |journal=Am J Gastroenterol |volume=99 |issue=3 |pages=523–6 |year=2004 |pmid=15056096 |doi=10.1111/j.1572-0241.2004.04067.x}}</ref>，[[驗屍|法醫病理]]的一系列研究則顯示此比率可能高達30%<ref name="autopsy" />。PSC增加膽管癌罹患風險的機制目前尚未明瞭。

特定的[[寄生蟲病|肝吸蟲疾病]]也是膽管癌的風險因子，[[香貓肝吸蟲|香貓肝吸蟲]]（分布於[[泰國|泰國]]、[[寮國|寮國]]、[[越南|越南]]）<ref>{{cite journal |vauthors=Watanapa P, Watanapa W |title=Liver fluke-associated cholangiocarcinoma |url=https://archive.org/details/sim_british-journal-of-surgery_2002-08_89_8/page/962 |journal=Br J Surg |volume=89 |issue=8 |pages=962–70 |year=2002 |pmid=12153620 |doi=10.1046/j.1365-2168.2002.02143.x}}</ref><ref name="pmid17622191">{{cite journal|vauthors=Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, Pairojkul C, Bhudhisawasdi V, Tesana S, Thinkamrop B, Bethony JM, Loukas A, Brindley PJ | title=Liver fluke induces cholangiocarcinoma| journal=PLoS Medicine| year=2007 | volume=4 | issue=7| pages=1148–1155| pmid=17622191 | doi= 10.1371/journal.pmed.0040201 | pmc=1913093}}</ref><ref name="pmid20624536">{{cite journal|vauthors=Sripa B, Kaewkes S, Intapan PM, Maleewong W, Brindley PJ | title=Food-borne trematodiases in Southeast Asia epidemiology, pathology, clinical manifestation and control| journal=Adv Parasitol| year=2010 | volume=72 | pages=305–350| pmid=20624536 | doi= 10.1016/S0065-308X(10)72011-X}}</ref>或中華肝吸蟲（分布於[[中國大陸|中國大陸]]、[[台灣|台灣]]、東[[西伯利亞|西伯利亞]]、[[韓國|韓國]]、[[越南|越南]]）<ref>{{cite journal |vauthors=Rustagi T, Dasanu CA |title=Risk Factors for Gallbladder Cancer and Cholangiocarcinoma: Similarities, Differences and Updates|journal=J Gastrointest Cancer |volume=43 |issue=2 |pages=137–147 |year=2012 |pmid=21597894 |doi=10.1007/s12029-011-9284-y}}</ref><ref>{{cite journal |vauthors=Hong ST, Fang Y |title=''Clonorchis sinensis'' and clonorchiasis, an update|journal=Parasitol Int|volume=61 |issue=1 |pages=17–24 |year=2012 |pmid=21741496 |doi=10.1016/j.parint.2011.06.007}}</ref>感染已證實和膽管癌有關。病毒感染（如[[B型肝炎|B型肝炎]]或[[C型肝炎|C型肝炎]]）<ref>{{cite journal |vauthors=Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, Arase Y, Murashima N, Chayama K, Kumada H |title=Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis |journal=Cancer |volume=88 |issue=11 |pages=2471–7 |year=2000 |pmid=10861422 |doi=10.1002/1097-0142(20000601)88:11<2471::AID-CNCR7>3.0.CO;2-T}}</ref><ref>{{cite journal |vauthors=Yamamoto S, Kubo S, Hai S, Uenishi T, Yamamoto T, Shuto T, Takemura S, Tanaka H, Yamazaki O, Hirohashi K, Tanaka T |title=Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma |journal=Cancer Sci |volume=95 |issue=7 |pages=592–5 |year=2004 |pmid=15245596 |doi=10.1111/j.1349-7006.2004.tb02492.x}}</ref><ref>{{cite journal |vauthors=Lu H, Ye M, Thung S, Dash S, Gerber M |title=Detection of hepatitis C virus RNA sequences in cholangiocarcinomas in Chinese and American patients |journal=Chin Med J (Engl) |volume=113 |issue=12 |pages=1138–41 |year=2000 |pmid=11776153}}</ref>、酒精性肝炎、[[肝硬化|肝硬化]]或其他形式的慢性肝臟疾病，都會大幅提升患者罹患膽管癌的風險<ref name="riskfactors" /><ref>{{cite journal |vauthors=Sorensen H, Friis S, Olsen J, Thulstrup A, Mellemkjaer L, Linet M, Trichopoulos D, Vilstrup H, Olsen J |title=Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark |url=https://archive.org/details/sim_hepatology_1998-10_28_4/page/921 |journal=Hepatology |volume=28 |issue=4 |pages=921–5 |year=1998 |pmid=9755226 |doi=10.1002/hep.510280404}}</ref>。一份研究中指出[[愛滋病毒|愛滋病]]也可能是膽管癌的風險因子，但目前還不清楚此現象是愛滋病毒本身還是相關的干擾因子（如C型肝炎感染）所造成的<ref name="riskfactors" />。{{le|膽型螺旋桿菌|Helicobacter bilis}}和{{le|肝型螺旋桿菌|Helicobacter hepaticus}}等細菌感染也可能造成膽道癌症<ref name="ChangParsonnet2010">{{cite journal|last1=Chang|first1=A. H.|last2=Parsonnet|first2=J.|title=Role of Bacteria in Oncogenesis|journal=Clinical Microbiology Reviews|volume=23|issue=4|year=2010|pages=837–857|issn=0893-8512|doi=10.1128/CMR.00012-10|pmid=20930075|pmc=2952975}}</ref>。

{{le|先天性肝內膽道囊腫|Caroli's syndrome}}（五種{{le|膽道囊腫| choledochal cysts}}中的一種）患者一生罹患膽管癌的概率为15%<ref>{{cite journal |vauthors=Lipsett P, Pitt H, Colombani P, Boitnott J, Cameron J |title=Choledochal cyst disease. A changing pattern of presentation |url=https://archive.org/details/sim_annals-of-surgery_1994-11_220_5/page/644 |journal=Ann Surg |volume=220 |issue=5 |pages=644–52 |year=1994 |pmid=7979612 |doi=10.1097/00000658-199411000-00007 |pmc=1234452}}</ref><ref>{{cite journal |vauthors=Dayton M, Longmire W, Tompkins R |title=Caroli's Disease: a premalignant condition? |journal=Am J Surg |volume=145 |issue=1 |pages=41–8 |year=1983 |pmid=6295196 |doi=10.1016/0002-9610(83)90164-2}}</ref>；罕見的{{le|遺傳性非息肉結腸癌|Lynch syndrome}}和膽道乳突瘤也可能和膽管癌有關<ref>{{cite journal |doi=10.1002/cncr.2820690508 |vauthors=Mecklin J, Järvinen H, Virolainen M |title=The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma |journal=Cancer |volume=69 |issue=5 |pages=1112–4 |year=1992 |pmid=1310886}}</ref><ref>{{cite journal |vauthors=Lee S, Kim M, Lee S, Jang S, Song M, Kim K, Kim H, Seo D, Song D, Yu E, Lee S, Min Y |title=Clinicopathologic review of 58 patients with biliary papillomatosis |journal=Cancer |volume=100 |issue=4 |pages=783–93 |year=2004 |pmid=14770435 |doi=10.1002/cncr.20031}}</ref>。[[膽結石|膽結石]]和膽管癌沒有明顯的關聯；{{le|肝內膽管結石|hepatolithiasis }}和膽管癌卻強烈相關，後者在西方國家並不常見，但在亞洲部分地區（如[[臺灣|臺灣]]）卻非常普遍<ref>{{cite journal |vauthors=Lee C, Wu C, Chen G |title=What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? |url=https://archive.org/details/sim_journal-of-gastroenterology-and-hepatology_2002_17_9/page/1015 |journal=J Gastroenterol Hepatol |volume=17 |issue=9 |pages=1015–20 |year=2002 |pmid=12167124 |doi=10.1046/j.1440-1746.2002.02779.x}}</ref><ref>{{cite journal |vauthors=Su C, Shyr Y, Lui W, P'Eng F |title=Hepatolithiasis associated with cholangiocarcinoma |url=https://archive.org/details/sim_british-journal-of-surgery_1997-07_84_7/page/969 |journal=Br J Surg |volume=84 |issue=7 |pages=969–73 |year=1997 |pmid=9240138 |doi=10.1002/bjs.1800840717}}</ref><ref>{{cite journal |vauthors=Donato F, Gelatti U, Tagger A, Favret M, Ribero M, Callea F, Martelli C, Savio A, Trevisi P, Nardi G |title=Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy |journal=Cancer Causes Control |volume=12 |issue=10 |pages=959–64 |year=2001 |pmid=11808716 |doi=10.1023/A:1013747228572}}</ref>。[[二氧化釷|二氧化釷]]以前常用作放射造影的對比劑，但人體受暴露後的30至40年內可能會產生膽管癌，[[美國|美國]]為此已於1950年代禁用此藥品<ref>{{cite journal |vauthors=Sahani D, Prasad S, Tannabe K, Hahn P, Mueller P, Saini S |title=Thorotrast-induced cholangiocarcinoma: case report |journal=Abdom Imaging |volume=28 |issue=1 |pages=72–4 |year= 2003|pmid=12483389 |doi=10.1007/s00261-001-0148-y}}</ref><ref>{{cite journal |vauthors=Zhu A, Lauwers G, Tanabe K |title=Cholangiocarcinoma in association with Thorotrast exposure |journal=J Hepatobiliary Pancreat Surg |volume=11 |issue=6 |pages=430–3 |year=2004 |pmid=15619021 |doi=10.1007/s00534-004-0924-5}}</ref>。

==病理生理學==
[[File:Digestive_system_showing_bile_duct.svg|thumb]]
膽管癌可能影響膽管中的任何位置'''──'''包括肝臟內和肝臟外：發生在肝臟內者稱肝內膽管癌；在肝臟外者稱肝外膽管癌；在肝外膽管與肝臟相接處者稱肝門膽管癌。膽管癌若發生在左右兩肝管匯流形成總肝管處（即膽囊三角內），則稱為{{le|克拉茨金瘤|Klatskin tumor}}（Klatskin tumor）<ref>{{cite journal |author=Klatskin G |title=Adenocarcinoma Of The Hepatic Duct At Its Bifurcation Within The Porta Hepatis. An Unusual Tumor With Distinctive Clinical And Pathological Features |url=https://archive.org/details/sim_american-journal-of-medicine_1965-02_38_2/page/241 |journal=Am J Med |volume=38 |issue= 2|pages=241–56 |year= 1965|pmid=14256720 |doi=10.1016/0002-9343(65)90178-6}}</ref>。

雖然膽管癌在膽道[[上皮組織|上皮]]有[[腺癌|腺癌]]的組織和分子特徵，但細胞真正的來源仍屬未知，有證據指出造成腫瘤的初始轉型細胞可能來自[[多能性|多能性]]肝[[幹細胞|幹細胞]]<ref>{{cite journal |author=Roskams T |title=Liver stem cells and their implication in hepatocellular and cholangiocarcinoma |journal=Oncogene |volume=25 |issue=27 |pages=3818–22 |year=2006 |pmid=16799623 |doi=10.1038/sj.onc.1209558}}</ref><ref>{{cite journal |vauthors=Liu C, Wang J, Ou Q |title=Possible stem cell origin of human cholangiocarcinoma |journal=World J Gastroenterol |volume=10 |issue=22 |pages=3374–6 |year=2004 |pmid=15484322}}</ref><ref>{{cite journal |vauthors=Sell S, Dunsford H |title=Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma |url=https://archive.org/details/sim_american-journal-of-pathology_1989-06_134_6/page/1347 |journal=Am J Pathol |volume=134 |issue=6 |pages=1347–63 |year=1989 |pmid=2474256 |pmc=1879951}}</ref>。膽管癌的發展可分為以下幾個階段：早期的[[增生_(生物學)|增生]]和[[化生|化生]]、接著[[異生|異生]]、最後發展成腫瘤，這個過程和[[結腸癌|結腸癌]]的發展相似<ref name="targeting">{{cite journal |author=Sirica A |title=Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy |journal=Hepatology |volume=41 |issue=1 |pages=5–15 |year=2005 |pmid=15690474 |doi=10.1002/hep.20537}}</ref>。慢性發炎和膽管阻塞會造成膽汁流動受阻，這可能也會促進膽管癌發展<ref name="targeting" /><ref>{{cite journal |vauthors=Holzinger F, Z'graggen K, Büchler M |title=Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma |journal=Ann Oncol |volume=10 |issue=Suppl 4 |pages=122–6 |year= 1999|pmid=10436802 |doi=10.1023/A:1008321710719}}</ref><ref>{{cite journal |author=Gores G |title=Cholangiocarcinoma: current concepts and insights |url=https://archive.org/details/sim_hepatology_2003-05_37_5/page/961 |journal=Hepatology |volume=37 |issue=5 |pages=961–9 |year=2003 |pmid=12717374 |doi=10.1053/jhep.2003.50200}}</ref>。

在[[組織學|組織學]]上，膽管癌的細胞可能以未分化型、分化型、或過渡型出現，它們通常由活化的[[纤维化|纖維結締組織]]或{{le|促結締組織|desmoplastic}}包圍，纖維化組織的存在使得分化型癌細胞和正常上皮細胞不易分辨。[[角蛋白|角蛋白]]、[[癌胚抗原|癌胚抗原]]和[[粘蛋白|粘蛋白]]染色或許能幫助診斷，但目前沒有專門的[[免疫組織化學|免疫組織化學]]染色能區分惡性和良性的膽道組織<ref name="nejm">{{cite journal |vauthors=de Groen P, Gores G, LaRusso N, Gunderson L, Nagorney D |title=Biliary tract cancers |journal=N Engl J Med |volume=341 |issue=18 |pages=1368–78 |year=1999 |pmid=10536130 |doi=10.1056/NEJM199910283411807}}</ref>。

==診斷==
[[File:Cholangiocarcinoma_-_high_mag.jpg|thumb]]]]
膽管癌的確切病程必須由病理檢查來判定，意即必須進行[[活體組織切片|組織切片]]或檢驗手術以取得腫瘤組織<ref name="Weber 2002">{{cite journal |vauthors=Weber S, DeMatteo R, Fong Y, Blumgart L, Jarnagin W |title=Staging Laparoscopy in Patients With Extrahepatic Biliary Carcinoma: Analysis of 100 Patients |url=https://archive.org/details/sim_annals-of-surgery_2002-03_235_3/page/392 |journal=Ann Surg |volume=235 |issue=3 |pages=392–9 |year=2002 |pmid=11882761 |doi=10.1097/00000658-200203000-00011 |pmc=1422445}}</ref>。阻塞性黃疸的病人可能疑似患有膽管癌，其中[[原發性硬化性膽管炎|原發性硬化性膽管炎]]是造成膽管癌的高風險因子，但它本身的症狀和膽管癌難以分辨，在這種情形下，造影上顯示的團狀物或膽管擴張等診斷線索不具有代表性，因此要有效診斷出膽管癌相當困難<ref name="Razumilava 2011">{{cite journal|last1=Razumilava|first1=Nataliya|last2=Gores|first2=Gregory J.|last3=Lindor|first3=Keith D.|title=Cancer surveillance in patients with primary sclerosing cholangitis|journal=Hepatology|volume=54|issue=5|year=2011|pages=1842–1852|issn=02709139|doi=10.1002/hep.24570}}</ref>
。

===血液檢查===
目前沒有特定的[[血液檢查|血液檢查]]方法能直接診斷出膽管癌。膽管癌患者血漿中的[[癌胚抗原|癌胚抗原]]和[[CA19-9|CA19-9]]濃度通常會提高，但其專一度和敏感度都不足以成為常規的檢查標準。血液檢查常配合造影方法，在疑似膽管癌的案例中作為有用的判斷依據<ref>以下研究顯示了非原發性硬化性膽管炎引發的膽管癌有關的血液指標（如CA19-9）和其表現量：
* {{cite journal |vauthors=Nehls O, Gregor M, Klump B |title=Serum and bile markers for cholangiocarcinoma |journal=Semin Liver Dis |volume=24 |issue=2 |pages=139–54 |year=2004 |pmid=15192787 |doi=10.1055/s-2004-828891}}
* {{cite journal |vauthors=Siqueira E, Schoen R, Silverman W, Martin J, Rabinovitz M, Weissfeld J, Abu-Elmaagd K, Madariaga J, Slivka A, Martini J |title=Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis |url=https://archive.org/details/sim_gastrointestinal-endoscopy_2002-07_56_1/page/40 |journal=Gastrointest Endosc |volume=56 |issue=1 |pages=40–7 |year=2002 |pmid=12085033 |doi=10.1067/mge.2002.125105}}
* {{cite journal |vauthors=Levy C, Lymp J, Angulo P, Gores G, Larusso N, Lindor K |title=The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis |url=https://archive.org/details/sim_digestive-diseases-and-sciences_2005-09_50_9/page/1734 |journal=Dig Dis Sci |volume=50 |issue=9 |pages=1734–40 |year=2005 |pmid=16133981 |doi=10.1007/s10620-005-2927-8}}
* {{cite journal |vauthors=Patel A, Harnois D, Klee G, LaRusso N, Gores G |title=The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis |url=https://archive.org/details/sim_american-journal-of-gastroenterology_2000-01_95_1/page/204 |journal=Am J Gastroenterol |volume=95 |issue=1 |pages=204–7 |year=2000 |pmid=10638584 |doi=10.1111/j.1572-0241.2000.01685.x}}</ref>。

===腹部造影===
[[File:CT_cholangioca.jpg|right]]顯示出膽管癌。]]
針對可疑的阻塞性黃疸患者，[[肝臟|肝臟]]和[[膽道|膽道]][[超音波|超音波]]常是首选的检查方法<ref>{{cite journal |author=Saini S |title=Imaging of the hepatobiliary tract |journal=N Engl J Med |volume=336 |issue=26 |pages=1889–94 |year=1997 |pmid=9197218 |doi=10.1056/NEJM199706263362607}}</ref><ref>{{cite journal |vauthors=Sharma M, Ahuja V |title=Aetiological spectrum of obstructive jaundice and diagnostic ability of ultrasonography: a clinician's perspective |journal=Trop Gastroenterol |volume=20 |issue=4 |pages=167–9 |year= 1999|pmid=10769604}}</ref>，超音波可以辨識出膽管阻塞和擴張，在某些案例中也足夠診斷出膽管癌<ref>{{cite journal |vauthors=Bloom C, Langer B, Wilson S |title=Role of US in the detection, characterization, and staging of cholangiocarcinoma |journal=Radiographics |volume=19 |issue=5 |pages=1199–218 |year= 1999|pmid=10489176 |doi=10.1148/radiographics.19.5.g99se081199}}</ref>。[[X射線電腦斷層掃描|X射線電腦斷層掃描]]（CT）在膽管癌的診斷中也充当重要角色<ref>{{cite journal |vauthors=Valls C, Gumà A, Puig I, Sanchez A, Andía E, Serrano T, Figueras J |title=Intrahepatic peripheral cholangiocarcinoma: CT evaluation |journal=Abdom Imaging |volume=25 |issue=5 |pages=490–6 |year= 2000|pmid=10931983 |doi=10.1007/s002610000079}}</ref><ref>{{cite journal |vauthors=Tillich M, Mischinger H, Preisegger K, Rabl H, Szolar D |title=Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma |journal=AJR Am J Roentgenol |volume=171 |issue=3 |pages=651–8 |year=1998 |pmid=9725291 |doi=10.2214/ajr.171.3.9725291}}</ref><ref>{{cite journal |vauthors=Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y |title=Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI |journal=J Comput Assist Tomogr |volume=23 |issue=5 |pages=670–7 |year= 1999|pmid=10524843 |doi=10.1097/00004728-199909000-00004}}</ref>。

===膽管造影===
[[File:ERCP_cholangioca.jpg|thumb]]
雖然腹部造影在膽管癌的診斷上很有用，但针对性的膽管造影也是必須的。最廣泛使用的膽管造影術為{{le|內視鏡逆行性膽胰管攝影術|Endoscopic retrograde cholangiopancreatography}}（ERCP），此種[[內視鏡|內視鏡]]必須由腸胃專科醫師或受過訓練的外科醫師操作，雖然這是一種有風險的侵入性方法，但它同時能取得[[活體組織切片|檢體]]、放置支架、或進行其他能排除膽管阻塞的措施<ref name="feldman2"/>。{{le|內視鏡超音波|Endoscopic ultrasound}}可以與ERCP同時進行，如此將能更準確地取得檢體、得知[[淋巴結|淋巴結]]的入侵情形、並評估手術切除的可行性<ref>{{cite journal |vauthors=Sugiyama M, Hagi H, Atomi Y, Saito M |title=Diagnosis of portal venous invasion by pancreatobiliary carcinoma: value of endoscopic ultrasonography |journal=Abdom Imaging |volume=22 |issue=4 |pages=434–8 |year= 1997|pmid=9157867 |doi=10.1007/s002619900227}}</ref>'''。'''除了ERCP外，{{le|經皮肝穿刺膽道造影|percutaneous transhepatic cholangiography}}（PTC）也是可行的選擇；{{le|核磁共振膽胰管造影|Magnetic resonance cholangiopancreatography}}（MRCP）則是一種非侵入性的替代方法<ref>{{cite journal |vauthors=Schwartz L, Coakley F, Sun Y, Blumgart L, Fong Y, Panicek D |title=Neoplastic pancreaticobiliary duct obstruction: evaluation with breath-hold MR cholangiopancreatography |journal=AJR Am J Roentgenol |volume=170 |issue=6 |pages=1491–5 |year=1998 |pmid=9609160 |doi=10.2214/ajr.170.6.9609160}}</ref><ref>{{cite journal |vauthors=Zidi S, Prat F, Le Guen O, Rondeau Y, Pelletier G |title=Performance characteristics of magnetic resonance cholangiography in the staging of malignant hilar strictures |journal=Gut |volume=46 |issue=1 |pages=103–6 |year=2000 |pmid=10601064 |doi=10.1136/gut.46.1.103 |pmc=1727781}}</ref><ref>{{cite journal |vauthors=Lee M, Park K, Shin Y, Yoon H, Sung K, Kim M, Lee S, Kang E |title=Preoperative evaluation of hilar cholangiocarcinoma with contrast-enhanced three-dimensional fast imaging with steady-state precession magnetic resonance angiography: comparison with intraarterial digital subtraction angiography |url=https://archive.org/details/sim_world-journal-of-surgery_2003-03_27_3/page/278 |journal=World J Surg |volume=27 |issue=3 |pages=278–83 |year=2003 |pmid=12607051 |doi=10.1007/s00268-002-6701-1}}</ref>，有些研究者建議以MRCP取代ERCP，因為MRCP能更精準地確認腫瘤並避免ERCP操作的風險<ref>{{cite journal |vauthors=Yeh T, Jan Y, Tseng J, Chiu C, Chen T, Hwang T, Chen M |title=Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings |url=https://archive.org/details/sim_american-journal-of-gastroenterology_2000-02_95_2/page/432 |journal=Am J Gastroenterol |volume=95 |issue=2 |pages=432–40 |year=2000 |pmid=10685746 |doi=10.1111/j.1572-0241.2000.01763.x}}</ref><ref>{{cite journal |vauthors=Freeman M, Sielaff T |title=A modern approach to malignant hilar biliary obstruction |journal=Rev Gastroenterol Disord |volume=3 |issue=4 |pages=187–201 |year=2003 |pmid=14668691}}</ref><ref>{{cite journal |vauthors=Szklaruk J, Tamm E, Charnsangavej C |title=Preoperative imaging of biliary tract cancers |journal=Surg Oncol Clin N Am |volume=11 |issue=4 |pages=865–76 |year=2002 |pmid=12607576 |doi=10.1016/S1055-3207(02)00032-7}}</ref>。

===手術===
[[File:Cholangiocarcinoma.png|right]]
[[外科手術|外科手術]]是取得[[活體組織切片|組織切片]]和準確得知膽管癌[[癌症分期|病程]]的唯一方法，分期[[腹腔鏡|腹腔鏡]]手術在特定情形下可以替代更具侵入性的{{le|剖腹手術|laparotomy}} <ref name="Weber 2002"/><ref>{{cite journal |vauthors=Callery M, Strasberg S, Doherty G, Soper N, Norton J |title=Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy |url=https://archive.org/details/sim_journal-of-the-american-college-of-surgeons_1997-07_185_1/page/33 |journal=J Am Coll Surg |volume=185 |issue=1 |pages=33–9 |year=1997 |pmid=9208958 |doi=10.1016/s1072-7515(97)00003-3}}</ref>；以{{le|楔狀切除術|Segmental resection|手術切除}}腫瘤是目前唯一能治癒膽管癌的方法，但只適用於尚未[[遠端轉移|遠端轉移]]的病患<ref name="resectibility">{{cite journal|vauthors=Tsao J, Nimura Y, Kamiya J, Hayakawa N, Kondo S, Nagino M, Miyachi M, Kanai M, Uesaka K, Oda K, Rossi R, Braasch J, Dugan J |title=Management of Hilar Cholangiocarcinoma: Comparison of an American and a Japanese Experience |url=https://archive.org/details/sim_annals-of-surgery_2000-08_232_2/page/166 |journal=Ann Surg |volume=232 |issue=2 |pages=166–74 |year=2000 |pmid=10903592 |doi=10.1097/00000658-200008000-00003 |pmc=1421125}}</ref>。

===病理===
膽管癌在組織學上歸類為中度到高度分化的[[腺癌|腺癌]]。[[免疫組織化學|免疫組織化學]]方法在診斷上很有用，能協助醫師區別膽管癌、[[肝細胞癌|肝細胞癌]]與其他腸胃道癌的後期轉移<ref>{{cite journal |vauthors=Länger F, von Wasielewski R, Kreipe HH |title=The importance of immunohistochemistry for the diagnosis of cholangiocarcinomas |language=de |journal=Pathologe |volume=27 |issue=4 |pages=244–50 |year=2006 |pmid=16758167 |doi=10.1007/s00292-006-0836-z}}</ref>。{{le|細胞病理學|Cytopathology|細胞刮削}}通常對膽管癌診斷的精確度很低<ref>Darwin PE, Kennedy A. {{EMedicine|med|343|Cholangiocarcinoma}}</ref>，這和癌細胞周圍{{le|結締組織增生|desmoplasia|促纖維細胞}}產生的基質有關<ref>{{cite journal |vauthors=Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA |title=Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis |journal=Gastrointestinal endoscopy |volume=81 |issue=1 |pages=168-176 |year=2014|doi=10.1016/j.gie.2014.09.017}}</ref>。

==分期==
目前至少有三種[[癌症分期|癌症分期]]系統用於膽管癌（Bismuth系統、Blumgart系統和{{le|美國癌症聯合委員會| American Joint Committee on Cancer }}的系統），但沒有一種能有效預測患者存活率<ref>{{cite journal |vauthors=Zervos E, Osborne D, Goldin S, Villadolid D, Thometz D, Durkin A, Carey L, Rosemurgy A |title=Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach |url=https://archive.org/details/sim_american-journal-of-surgery_2005-11_190_5/page/810 |journal=Am J Surg |volume=190 |issue=5 |pages=810–5 |year=2005 |pmid=16226963 |doi=10.1016/j.amjsurg.2005.07.025}}</ref>。癌症分期最重要的問題在於腫瘤能否成功地以{{le|楔狀切除術|Segmental resection|手術移除}}，但對膽管癌而言，答案通常要到手術進行當下才能判定。

一般而言，評估膽管癌手術可行性的原則如下<ref name="resectibility"/><ref>{{cite journal |vauthors=Rajagopalan V, Daines W, Grossbard M, Kozuch P |title=Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1 |journal=Oncology (Williston Park) |volume=18 |issue=7 |pages=889–96 |year=2004 |pmid=15255172}}</ref>：
*沒有[[淋巴結|淋巴結]]或[[肝臟|肝臟]][[遠端轉移|轉移]]
*沒有影響到肝門靜脈
*沒有直接侵犯到鄰近器官
*沒有大範圍的遠端轉移

==治療==
膽管癌是個難以醫治且快速致死的疾病，只有在腫瘤能以{{le|楔狀切除術| Segmental resection|手術根除}}的情況下才有機會治癒。除非已有明確證據指出患者無法進行手術，多數案例要到手術進行當下才能評估手術成功率<ref>{{cite journal|vauthors=Su C, Tsay S, Wu C, Shyr Y, King K, Lee C, Lui W, Liu T, P'eng F |title=Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma |url=https://archive.org/details/sim_annals-of-surgery_1996-04_223_4/page/384 |journal=Ann Surg |volume=223 |issue=4 |pages=384–94 |year=1996 |pmid=8633917 |doi=10.1097/00000658-199604000-00007 |pmc=1235134}}</ref>，因此患者多會先進行一次試探性手術<ref name="feldman2"/>。[[馬約診所|馬約診所]]使用標準化的肝臟移植手術和嚴格的手術篩選條件，在早期膽管癌治療中取得顯著的成功<ref>{{cite journal |author1=C. B. Rosen |author2=J. K. Heimbach |author3=G. J. Gores |title=Surgery for cholangiocarcinoma: the role of liver transplantation |journal=The Official Journal of the International Hepato Pancreato Biliary Association |pmc=2504373 |pmid=18773052 |doi=10.1080/13651820801992542 |volume=10 |issue=3 |year=2008 |pages=186–9}}</ref>；{{le|肝臟移植|Liver transplantation }}後的輔助性療法在無法切除腫瘤的特定個案中有明显的作用<ref>{{cite journal |vauthors=Heimbach JK, Gores GJ, Haddock MG, etal |title=Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma |journal=Transplantation |volume=82 |issue=12 |pages=1703–7 |date=December 2006 |pmid=17198263 |doi=10.1097/01.tp.0000253551.43583.d1 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0041-1337&volume=82&issue=12&spage=1703 |access-date=2016-07-21 |archive-date=2013-05-22 |archive-url=https://web.archive.org/web/20130522223146/http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0041-1337&volume=82&issue=12&spage=1703 |dead-url=no }}</ref>。

===輔助性化療和放療===
由於有高達85%的膽管癌患者在手術後三年內復發，患者術後常會使用輔助性[[化學療法|化療]]或[[放射治療|放療]]以期增加治癒機會<ref name=adjuvant1>{{cite journal |vauthors=Vogel A, Wege H, Caca K, Nashan B, Neumann U |title=The Diagnosis and Treatment of Cholangiocarcinoma|journal=Dtsch Arztebl Int |volume=111 |issue=44 |pages=748-754 |year=2014 |doi=10.3238/arztebl.2014.0748 |pmc=4239580}}</ref>。若術後腫瘤組織邊緣呈陰性反應（例如腫瘤已完全清除），輔助療法不一定能帶來好處，報告指出輔助性放療可能產生正面<ref>{{cite journal |vauthors=Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M, Fukao K |title=Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma |journal=Int J Radiat Oncol Biol Phys |volume=46 |issue=3 |pages=581–7 |year=2000 |pmid=10701737 |doi=10.1016/S0360-3016(99)00472-1}}</ref><ref>{{cite journal |vauthors=Alden M, Mohiuddin M |title=The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer |journal=Int J Radiat Oncol Biol Phys |volume=28 |issue=4 |pages=945–51 |year=1994 |pmid=8138448 |doi=10.1016/0360-3016(94)90115-5}}</ref>或負面<ref name="nakeeb"/><ref>{{cite journal |vauthors=González González D, Gouma D, Rauws E, van Gulik T, Bosma A, Koedooder C |title=Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma |journal=Ann Oncol |volume=10 |issue=Suppl 4 |pages=215–20 |year= 1999|pmid=10436826 |doi=10.1023/A:1008339709327}}</ref><ref>{{cite journal |vauthors=Pitt H, Nakeeb A, Abrams R, Coleman J, Piantadosi S, Yeo C, Lillemore K, Cameron J |title=Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival |url=https://archive.org/details/sim_annals-of-surgery_1995-06_221_6/page/788 |journal=Ann Surg |volume=221 |issue=6 |pages=788–97; discussion 797–8 |year=1995 |pmid=7794082 |doi=10.1097/00000658-199506000-00017 |pmc=1234714}}</ref>的結果；對於腫瘤已成功清除的病人而言，輔助性化療似乎也沒有意义<ref>{{cite journal |vauthors=Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T |title=Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma |journal=Cancer |volume=95 |issue=8 |pages=1685–95 |year=2002 |pmid=12365016 |doi=10.1002/cncr.10831}}</ref>。結合化療和放療的效果目前並不清楚<ref name=adjuvant2>{{cite journal |vauthors=Howell M, Valle JW|title= The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma|journal=Best Practice & Research Clinical Gastroenterology|volume=29 |issue=2 |pages=333-343 |year=2015 |pmid=10701737 |doi=10.1016/j.bpg.2015.03.001}}</ref>。若術後腫瘤組織邊緣呈陽性反應，代表腫瘤沒有根除，一般會建議進行輔助性放療和化療<ref name="nccn">{{PDFlink|[http://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf National Comprehensive Cancer Network (NCCN) guidelines on evaluation and treatment of hepatobiliary malignancies]|216 KB}}. Accessed 13 March 2007.</ref>。目前的研究結果顯示化療的效果似乎有優於放療的趨勢<ref name=adjuvant1 />，針對化療藥物[[吉西他濱|吉西他濱]]/[[順鉑|順鉑]]的第三期[[隨機對照試驗|隨機對照試驗]]已經在2014年註冊<ref>{{cite journal |vauthors=Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen HJ, ..., Shannon J |title=Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)-a randomized, multidisciplinary, multinational phase III trial|journal=BMC cancer |volume=15 |issue=1 |pages=1 |year=2015 |doi=10.1186/s12885-015-1498-0}}</ref>。

===後期治療===
膽管癌絕大多數的病例都無法以手術根除<ref >{{cite journal |vauthors=Vauthey J, Blumgart L |title=Recent advances in the management of cholangiocarcinomas |url=https://archive.org/details/sim_seminars-in-liver-disease_1994-05_14_2/page/109 |journal=Semin. Liver Dis. |volume=14 |issue=2 |pages=109–14 |year=1994 |pmid=8047893 |doi=10.1055/s-2007-1007302}}</ref>，患者通常會接受緩和性[[化療|化療]]，也可能配合[[放射治療|放射治療]]。[[隨機對照試驗|隨機對照試驗]]的結果顯示化療在這些患者中能增進生活品質並延長壽命<ref>{{cite journal |vauthors=Glimelius B, Hoffman K, Sjödén P, Jacobsson G, Sellström H, Enander L, Linné T, Svensson C |title=Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer |url=https://archive.org/details/sim_annals-of-oncology_1996-08_7_6/page/593 |journal=Ann Oncol |volume=7 |issue=6 |pages=593–600 |year=1996 |pmid=8879373 |doi=10.1093/oxfordjournals.annonc.a010676}}</ref>。目前沒有單一的化療用藥常規，若狀況允許，也常會建議患者申請[[臨床試驗|臨床試驗]]<ref name="nccn" />。治療膽管癌的化療藥物包括[[5-氟尿嘧啶|5-氟尿嘧啶]]/{{le|亞葉酸|Leucovorin}} <ref>{{cite journal |vauthors=Choi C, Choi I, Seo J, Kim B, Kim J, Kim C, Um S, Kim J, Kim Y |title=Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas |journal=Am J Clin Oncol |volume=23 |issue=4 |pages=425–8 |year=2000 |pmid=10955877 |doi=10.1097/00000421-200008000-00023}}</ref>、單用[[吉西他濱|吉西他濱]] <ref>{{cite journal |vauthors=Park J, Oh S, Kim S, Kwon H, Kim J, Jin-Kim H, Kim Y |title=Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study |journal=Jpn J Clin Oncol |volume=35 |issue=2 |pages=68–73 |year=2005 |pmid=15709089 |doi=10.1093/jjco/hyi021}}</ref>或吉西他濱加上[[順鉑|順鉑]] <ref>{{cite journal |vauthors=Giuliani F, Gebbia V, Maiello E, Borsellino N, Bajardi E, Colucci G |title=Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM) |journal=Ann Oncol |volume=17 |issue=Suppl 7 |pages=vii73–7 |year= 2006|pmid=16760299 |doi=10.1093/annonc/mdl956}}</ref>、[[愛萊諾迪肯|愛萊諾迪肯]]<ref>{{cite journal |vauthors=Bhargava P, Jani C, Savarese D, O'Donnell J, Stuart K, Rocha Lima C |title=Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report |journal=Oncology (Williston Park) |volume=17 |issue=9 Suppl 8 |pages=23–6 |year=2003 |pmid=14569844}}</ref>或[[卡培他濱|卡培他濱]]<ref>{{cite journal |vauthors=Knox J, Hedley D, Oza A, Feld R, Siu L, Chen E, Nematollahi M, Pond G, Zhang J, Moore M |title=Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial |journal=J Clin Oncol |volume=23 |issue=10 |pages=2332–8 |year=2005 |pmid=15800324 |doi=10.1200/JCO.2005.51.008}}</ref>。一個小型的可行性研究指出[[酪氨酸激酶抑制劑|酪氨酸激酶抑制劑]][[厄洛替尼|厄洛替尼]]在後期膽管癌患者中可能是有益的<ref>{{cite journal |vauthors=Philip P, Mahoney M, Allmer C, Thomas J, Pitot H, Kim G, Donehower R, Fitch T, Picus J, Erlichman C |title=Phase II study of erlotinib in patients with advanced biliary cancer |journal=J Clin Oncol |volume=24 |issue=19 |pages=3069–74 |year=2006 |pmid=16809731 |doi=10.1200/JCO.2005.05.3579}}</ref>。

==病程==
以{{le|楔狀切除術| Segmental resection|手術移除}}腫瘤是目前唯一可能治癒膽管癌的方法。由於癌細胞會透過淋巴結[[遠端轉移|遠端轉移]]，無法切除腫瘤的患者[[五年存活率|五年存活率]]為0%<ref>{{cite journal |vauthors=Yamamoto M, Takasaki K, Yoshikawa T |title=Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma |journal=Japanese Journal of Clinical Oncology |volume=29 |issue=3 |pages=147–150 |year=1999 |doi=10.1093/jjco/29.3.147 |pmid=10225697}}</ref>；全部膽管癌患者的五年存活率則為5%<ref>{{cite journal |vauthors=Farley D, Weaver A, Nagorney D |title="Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention |url=https://archive.org/details/sim_mayo-clinic-proceedings_1995-05_70_5/page/425 |journal=Mayo Clin Proc |volume=70 |issue=5 |pages=425–9 |year=1995 |pmid=7537346 |doi=10.4065/70.5.425}}</ref>。若無法切除的腫瘤藉由肝內膽管或[[肝門靜脈|肝門靜脈]]侵犯肝臟，即使患者其餘生理機能正常，其餘命的中位數也小於6個月<ref>{{cite journal |vauthors=Grove MK, Hermann RE, Vogt DP, Broughan TA |title=Role of radiation after operative palliation in cancer of the proximal bile ducts |url=https://archive.org/details/sim_american-journal-of-surgery_1991-04_161_4/page/454 |journal=Am J Surg |volume=161| pages=454–458 |year=1991 |doi= 10.1016/0002-9610(91)91111-U |pmid= 1709795 |issue= 4}}</ref>。

對能進行手術的病例而言，手術成功的機率取決於腫瘤的位置，以及腫瘤是否能加以根除。遠端型膽管癌（腫瘤發生於{{Le|總膽管|Common bile duct}}）患者通常會進行{{le|胰十二指腸切除術|Whipple procedure}}，長期存活率為15%–25%，另有一系列報告指出腫瘤未侵犯到淋巴結的患者有54%的五年存活率<ref>以下為有關遠端膽管癌手術治療結果的研究：
* {{cite journal |vauthors=Nakeeb A, Pitt H, Sohn T, Coleman J, Abrams R, Piantadosi S, Hruban R, Lillemoe K, Yeo C, Cameron J |title=Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors |url=https://archive.org/details/sim_annals-of-surgery_1996-10_224_4/page/463 |journal=Ann Surg |volume=224 |issue=4 |pages=463–73; discussion 473–5 |year=1996 |pmid=8857851 |doi=10.1097/00000658-199610000-00005 |pmc=1235406}}
* {{cite journal |author=Nagorney D, Donohue J, Farnell M, Schleck C, Ilstrup D |title=Outcomes after curative resections of cholangiocarcinoma |journal=Arch Surg |volume=128 |issue=8 |pages=871–7; discussion 877–9 |year=1993 |pmid=8393652 |doi=10.1001/archsurg.1993.01420200045008}}
* {{cite journal |vauthors=Jang J, Kim S, Park D, Ahn Y, Yoon Y, Choi M, Suh K, Lee K, Park Y |title=Actual Long-term Outcome of Extrahepatic Bile Duct Cancer After Surgical Resection |url=https://archive.org/details/sim_annals-of-surgery_2005-01_241_1/page/77 |journal=Ann Surg |volume=241 |issue=1 |pages=77–84 |year=2005 |pmid=15621994 |pmc=1356849 |doi=10.1097/01.sla.0000150166.94732.88}}
* {{cite journal |vauthors=Bortolasi L, Burgart L, Tsiotos G, Luque-De León E, Sarr M |title=Adenocarcinoma of the distal bile duct. A clinicopathologic outcome analysis after curative resection |journal=Dig Surg |volume=17 |issue=1 |pages=36–41 |year=2000 |pmid=10720830 |doi=10.1159/000018798}}
* {{cite journal |vauthors=Fong Y, Blumgart L, Lin E, Fortner J, Brennan M |title=Outcome of treatment for distal bile duct cancer |url=https://archive.org/details/sim_british-journal-of-surgery_1996-12_83_12/page/1712 |journal=Br J Surg |volume=83 |issue=12 |pages=1712–5 |year=1996 |pmid=9038548 |doi=10.1002/bjs.1800831217}}</ref>。肝內膽管癌（腫瘤發生於肝內膽管）患者通常會將{{le|肝臟切除術|hepatectomy|部分肝臟移除}}，不同的系列報告估計術後存活率為22%–66%，存活率差異取決於手術移除的完整度和癌細胞是否侵犯到淋巴結<ref>下列研究指出了肝內膽管癌的治療結果：
* {{cite journal |vauthors=Nakeeb A, Pitt H, Sohn T, Coleman J, Abrams R, Piantadosi S, Hruban R, Lillemoe K, Yeo C, Cameron J |title=Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors |url=https://archive.org/details/sim_annals-of-surgery_1996-10_224_4/page/463 |journal=Ann Surg |volume=224 |issue=4 |pages=463–73; discussion 473–5 |year=1996 |pmid=8857851 |doi=10.1097/00000658-199610000-00005 |pmc=1235406}}
* {{cite journal |author=Lieser M, Barry M, Rowland C, Ilstrup D, Nagorney D |title=Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience |journal=J Hepatobiliary Pancreat Surg |volume=5 |issue=1 |pages=41–7 |year=1998 |pmid=9683753 |doi=10.1007/PL00009949}}
* {{cite journal |vauthors=Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou J, Belghiti J |title=Resection of intrahepatic cholangiocarcinoma: a Western experience |journal=J Hepatobiliary Pancreat Surg |volume=6 |issue=2 |pages=122–7 |year=1999 |pmid=10398898 |doi=10.1007/s005340050094}}
* {{cite journal |vauthors=Nakagohri T, Asano T, Kinoshita H, Kenmochi T, Urashima T, Miura F, Ochiai T |title=Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma |url=https://archive.org/details/sim_world-journal-of-surgery_2003-03_27_3/page/289 |journal=World J Surg |volume=27 |issue=3 |pages=289–93 |year=2003 |pmid=12607053 |doi=10.1007/s00268-002-6696-7}}
* {{cite journal |vauthors=Weber S, Jarnagin W, Klimstra D, DeMatteo R, Fong Y, Blumgart L |title=Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes |journal=J Am Coll Surg |volume=193 |issue=4 |pages=384–91 |year=2001 |pmid=11584966 |doi=10.1016/S1072-7515(01)01016-X}}</ref>。肝門型膽管癌（腫瘤發生於肝外膽管與肝臟相接處，又稱{{le|克拉茨金瘤|Klatskin tumor}}）通常無法進行手術，只有少數罕見的病例有開刀治療的可能，手術過程通常會包括{{le|膽囊切除術| cholecystectomy }}或部分肝臟移除，能進行手術的肝門型膽管癌患者五年存活率為20%–50%<ref>以下報告估算了肝門型膽管癌患者的術後存活率：
* {{cite journal |vauthors=Burke E, Jarnagin W, Hochwald S, Pisters P, Fong Y, Blumgart L |title=Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system |url=https://archive.org/details/sim_annals-of-surgery_1998-09_228_3/page/385 |journal=Ann Surg |volume=228 |issue=3 |pages=385–94 |year=1998 |pmid=9742921 |doi=10.1097/00000658-199809000-00011 |pmc=1191497}}
* {{cite journal |vauthors=Tsao J, Nimura Y, Kamiya J, Hayakawa N, Kondo S, Nagino M, Miyachi M, Kanai M, Uesaka K, Oda K, Rossi R, Braasch J, Dugan J |title=Management of Hilar Cholangiocarcinoma: Comparison of an American and a Japanese Experience |url=https://archive.org/details/sim_annals-of-surgery_2000-08_232_2/page/166 |journal=Ann Surg |volume=232 |issue=2 |pages=166–74 |year=2000 |pmid=10903592 |doi=10.1097/00000658-200008000-00003 |pmc=1421125}}
* {{cite journal |vauthors=Chamberlain R, Blumgart L |title=Hilar cholangiocarcinoma: a review and commentary |journal=Ann Surg Oncol |volume=7 |issue=1 |pages=55–66 |year= 2000|pmid=10674450 |doi=10.1007/s10434-000-0055-4}}
* {{cite journal |vauthors=Washburn W, Lewis W, Jenkins R |title=Aggressive surgical resection for cholangiocarcinoma |journal=Arch Surg |volume=130 |issue=3 |pages=270–6 |year=1995 |pmid=7534059 |doi=10.1001/archsurg.1995.01430030040006}}
* {{cite journal |vauthors=Nagino M, Nimura Y, Kamiya J, Kanai M, Uesaka K, Hayakawa N, Yamamoto H, Kondo S, Nishio H |title=Segmental liver resections for hilar cholangiocarcinoma |journal=Hepatogastroenterology |volume=45 |issue=19 |pages=7–13 |year= 1998|pmid=9496478}}
* {{cite journal |vauthors=Rea D, Munoz-Juarez M, Farnell M, Donohue J, Que F, Crownhart B, Larson D, Nagorney D |title=Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients |journal=Arch Surg |volume=139 |issue=5 |pages=514–23; discussion 523–5 |year=2004 |pmid=15136352 |doi=10.1001/archsurg.139.5.514}}
* {{cite journal |vauthors=Launois B, Reding R, Lebeau G, Buard J |title=Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers |journal=J Hepatobiliary Pancreat Surg |volume=7 |issue=2 |pages=128–34 |year=2000 |pmid=10982604 |doi=10.1007/s005340050166}}</ref>。

由[[原發性硬化性膽管炎|原發性硬化性膽管炎]]發展而來的膽管癌患者情況通常更糟，這或許是因為腫瘤在診斷出來前就已經惡化<ref name="autopsy"/><ref>{{cite journal |vauthors=Kaya M, de Groen P, Angulo P, Nagorney D, Gunderson L, Gores G, Haddock M, Lindor K |title=Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience |url=https://archive.org/details/sim_american-journal-of-gastroenterology_2001-04_96_4/page/1164 |journal=Am J Gastroenterol |volume=96 |issue=4 |pages=1164–9 |year=2001 |pmid=11316165 |doi=10.1111/j.1572-0241.2001.03696.x}}</ref>。一些臨床證據指出入侵性較高的手術和佐劑治療可能會有較好的效果<ref>{{cite journal |vauthors=Nakeeb A, Tran K, Black M, Erickson B, Ritch P, Quebbeman E, Wilson S, Demeure M, Rilling W, Dua K, Pitt H |title=Improved survival in resected biliary malignancies |url=https://archive.org/details/sim_surgery_2002-10_132_4/page/555 |journal=Surgery |volume=132 |issue=4 |pages=555–63; discission 563–4 |year=2002 |pmid=12407338 |doi=10.1067/msy.2002.127555}}</ref>。

==流行病學==
[[File:Cholangiocarcinoma_incidence_zh-tw.svg|thumb]]

膽管癌是一種相對少見的癌症，美國每年大約有2000到3000樁新病例，換算成年[[發生率_(流行病學)|發生率]]約每十萬人1至2例<ref name="Landis">{{cite journal |vauthors=Landis S, Murray T, Bolden S, Wingo P |title=Cancer statistics, 1998 |journal=CA Cancer J Clin |volume=48 |issue=1 |pages=6–29 |year= 1998|pmid=9449931 |doi=10.3322/canjclin.48.1.6}}</ref>，[[驗屍|法醫病理]]研究指出[[盛行率|盛行率]]約0.01% - 0.46%<ref>{{cite journal |vauthors=Vauthey J, Blumgart L |title=Recent advances in the management of cholangiocarcinomas |url=https://archive.org/details/sim_seminars-in-liver-disease_1994-05_14_2/page/109 |journal=Semin Liver Dis |volume=14 |issue=2 |pages=109–14 |year=1994 |pmid=8047893 |doi=10.1055/s-2007-1007302}}</ref><ref>{{Cite web |url=http://www.cancer.gov/statistics/ |title=Cancer Statistics Home Page — National Cancer Institute<!-- Bot generated title --> |accessdate=2016-07-21 |archive-date=2015-04-29 |archive-url=https://web.archive.org/web/20150429031005/http://www.cancer.gov/statistics/ |dead-url=no }}</ref>。由於區域性流行病的緣故，膽管癌在亞洲有較高的流行率，在[[上海|上海]]、[[韓國|韓國]]和[[泰國|泰國]]北部的發生率都已超過罕見癌症的標準（大於每年每十萬人6例）<ref name=":0">{{cite journal |vauthors= Bragazzi MC, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, Gaudio E, Alvaro D |title=Cholangiocarcinoma: epidemiology and risk factors|journal=Translational Gastrointestinal Cancer |volume=1 |issue=1 |pages=21–32|year=2011 |doi=10.3978/j.issn.2224-4778.2011.11.04}}</ref>，尤其是泰國北部的年發生率高達每十萬人14.6例以上，[[統合分析|統合分析]]研究指出[[中華肝吸蟲|中華肝吸蟲]]和[[香貓肝吸蟲|香貓肝吸蟲]]是最主要的風險因子<ref name="asia">{{cite journal |vauthors=Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, Sripa B, Hong ST|title=Epidemiology of cholangiocarcinoma: an update focusing on risk factors |journal=Cancer Science |volume=101 |issue=3 |pages=579–585|year=2010 |pmid=20085587 |doi=10.1111/j.1349-7006.2009.01458.x}}</ref>。[[台灣|台灣]]的膽管癌年發生率為每十萬人4.7例，屬於罕見癌症，但發生率仍較西方國家高出許多，台灣的中華肝吸蟲感染盛行率雖然已經大幅降低，但另一項西方國家很少見的風險因子——{{le|肝內膽管結石|hepatolithiasis}}和台灣的膽管癌病例則有強烈關聯<ref name="asia" />。

膽管癌的發生率會隨著年齡增加，男性發生的機率稍微較女性高（可能是因為男性有較高比例的原發性硬化性膽管炎患者）<ref name=autogenerated1>{{cite journal |vauthors=Henson D, Albores-Saavedra J, Corle D |title=Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates |journal=Cancer |volume=70 |issue=6 |pages=1498–501 |year=1992 |pmid=1516001 |doi=10.1002/1097-0142(19920915)70:6<1498::AID-CNCR2820700609>3.0.CO;2-C}}</ref>。根據法醫病理研究，帶有[[原發性硬化性膽管炎|原發性硬化性膽管炎]]的患者膽管癌流行率可能高達30%<ref name="autopsy">{{cite journal |vauthors=Rosen C, Nagorney D, Wiesner R, Coffey R, LaRusso N |title=Cholangiocarcinoma complicating primary sclerosing cholangitis |journal=Ann Surg |volume=213 |issue=1 |pages=21–5 |year=1991 |pmid=1845927 |doi=10.1097/00000658-199101000-00004 |pmc=1358305}}</ref>。多份研究紀錄指出截至二十世紀末為止，[[北美|北美]]、[[歐洲|歐洲]]、[[亞洲|亞洲]]和[[澳洲|澳洲]]的肝內膽管癌發生率都有上升的趨勢<ref>有關二十世紀末膽管癌發生率的論文如下：
* {{cite journal |author=Patel T |title=Worldwide trends in mortality from biliary tract malignancies |journal=BMC Cancer |volume=2|pages=10 |year= 2002|pmid=11991810 |doi=10.1186/1471-2407-2-10 |pmc=113759}}
* {{cite journal |author=Patel T |title=Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States |url=https://archive.org/details/sim_hepatology_2001-06_33_6/page/1353 |journal=Hepatology |volume=33 |issue=6 |pages=1353–7 |year=2001 |pmid=11391522 |doi=10.1053/jhep.2001.25087}}
* {{cite journal |vauthors=Shaib Y, Davila J, McGlynn K, El-Serag H |title=Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? |journal=J Hepatol |volume=40 |issue=3 |pages=472–7 |year=2004 |pmid=15123362 |doi=10.1016/j.jhep.2003.11.030}}
* {{cite journal |vauthors=West J, Wood H, Logan R, Quinn M, Aithal G |title=Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001 |journal=Br J Cancer |volume=94 |issue=11 |pages=1751–8 |year=2006 |pmid=16736026 |doi=10.1038/sj.bjc.6603127 |pmc=2361300}}
* {{cite journal |vauthors=Khan S, Taylor-Robinson S, Toledano M, Beck A, Elliott P, Thomas H |title=Changing international trends in mortality rates for liver, biliary and pancreatic tumours |journal=J Hepatol |volume=37 |issue=6 |pages=806–13 |year=2002 |pmid=12445422 |doi=10.1016/S0168-8278(02)00297-0}}
* {{cite journal |vauthors=Welzel T, McGlynn K, Hsing A, O'Brien T, Pfeiffer R |title=Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States |journal=J Natl Cancer Inst |volume=98 |issue=12 |pages=873–5 |year=2006 |pmid=16788161 |doi=10.1093/jnci/djj234}}</ref>，並於2000年後逐漸趨於穩定<ref name="BanalesCardinale2016"/>，肝內膽管癌發生率上升的原因目前並不清楚，診斷方法的進步可能有關，但潛在風險因子的盛行率（例如[[愛滋病|愛滋病]]感染）在同個時期也有增加，因此可能也扮演一定的角色<ref name="riskfactors">{{cite journal |vauthors=Shaib Y, El-Serag H, Davila J, Morgan R, McGlynn K |title=Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study |url=https://archive.org/details/sim_gastroenterology_2005-03_128_3/page/620 |journal=Gastroenterology |volume=128 |issue=3 |pages=620–6 |year=2005 |pmid=15765398 |doi=10.1053/j.gastro.2004.12.048}}</ref>。然而，近年來肝外膽管癌和肝門膽管癌的發生率卻呈現下降的趨勢<ref name="BanalesCardinale2016">{{cite journal|last1=Banales|first1=Jesus M.|last2=Cardinale|first2=Vincenzo|last3=Carpino|first3=Guido|last4=Marzioni|first4=Marco|last5=Andersen|first5=Jesper B.|last6=Invernizzi|first6=Pietro|last7=Lind|first7=Guro E.|last8=Folseraas|first8=Trine|last9=Forbes|first9=Stuart J.|last10=Fouassier|first10=Laura|last11=Geier|first11=Andreas|last12=Calvisi|first12=Diego F.|last13=Mertens|first13=Joachim C.|last14=Trauner|first14=Michael|last15=Benedetti|first15=Antonio|last16=Maroni|first16=Luca|last17=Vaquero|first17=Javier|last18=Macias|first18=Rocio I. R.|last19=Raggi|first19=Chiara|last20=Perugorria|first20=Maria J.|last21=Gaudio|first21=Eugenio|last22=Boberg|first22=Kirsten M.|last23=Marin|first23=Jose J. G.|last24=Alvaro|first24=Domenico|title=Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)|journal=Nature Reviews Gastroenterology & Hepatology|volume=13|issue=5|year=2016|pages=261–280|issn=1759-5045|doi=10.1038/nrgastro.2016.51}}</ref>。美國可能由於有完善的醫療照護，膽管癌患者的住院人數和院內死亡率也都趨於降低。<ref name="WadhwaJobanputra2016">{{cite journal|last1=Wadhwa|first1=Vaibhav|last2=Jobanputra|first2=Yash|last3=Thota|first3=Prashanthi N.|last4=Narayanan Menon|first4=K.V.|last5=Parsi|first5=Mansour A.|last6=Sanaka|first6=Madhusudhan R.|title=Healthcare utilization and costs associated with cholangiocarcinoma|journal=Gastroenterology Report|year=2016|pages=gow026|issn=2052-0034|doi=10.1093/gastro/gow026}}</ref>

{| class="wikitable collapsible collapsed"  style="width:50%; margin:0.2em; float:center;"
|+ align="top" | 不同國家男性與女性的肝內膽管癌和肝外膽管癌{{le|年齡別死亡率|Age-standardized mortality rate}}<ref>{{cite journal |vauthors=Khan S, Taylor-Robinson S, Toledano M, Beck A, Elliott P, Thomas H |title=Changing international trends in mortality rates for liver, biliary and pancreatic tumours |journal=J Hepatol |volume=37 |issue=6 |pages=806–13 |year=2002 |pmid=12445422 |doi=10.1016/S0168-8278(02)00297-0}}</ref>
|-
! 國家
! 肝內膽管癌 (男/女)
! 肝外膽管癌 (男/女)
|-
! 美國
| style="text-align:center;"| 0.60 / 0.43
| style="text-align:center;"| 0.70 / 0.87
|-
! 日本
| style="text-align:center;"| 0.23 / 0.10
| style="text-align:center;"| 5.87 / 5.20
|-
! 澳洲
| style="text-align:center;"| 0.70 / 0.53
| style="text-align:center;"| 0.90 / 1.23
|-
! 英格蘭/威爾斯
| style="text-align:center;"| 0.83 / 0.63
| style="text-align:center;"| 0.43 / 0.60
|-
! 蘇格蘭
| style="text-align:center;"| 1.17 / 1.00
| style="text-align:center;"| 0.60 / 0.73
|-
! 法國
| style="text-align:center;"| 0.27 / 0.20
| style="text-align:center;"| 1.20 / 1.37
|-
! 義大利
| style="text-align:center;"| 0.13 / 0.13
| style="text-align:center;"| 2.10 / 2.60
|}

== 研究==
近期研究顯示不同患者的癌細胞具有高度的基因變異，這和腫瘤發生位置、造成疾病的風險因子等都有關聯<ref name="Cardinale 2012">{{cite journal|last1=Cardinale|first1=Vincenzo|title=Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity|journal=World Journal of Gastrointestinal Oncology|volume=4|issue=5|year=2012|pages=94|issn=1948-5204|doi=10.4251/wjgo.v4.i5.94}}</ref>，研究者正嘗試由手術切除的組織篩選患者腫瘤細胞的基因型，以施予患者特定的標靶藥物<ref>{{cite journal |vauthors=Voss J, Holtegaard L, Kerr S, Fritcher E, Roberts L, Gores G et al|title=Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions|url=https://archive.org/details/sim_human-pathology_2013-07_44_7/page/1216|journal=Human pathology|volume=44 |issue=7 |pages=1216-1222 |year=2013 |pmid=|doi=10.1016/j.humpath.2012.11.006}}</ref>。隨著膽管癌細胞生成和腫瘤微環境的可能分子路徑正式提出，阻斷這些路徑的抑制劑也成為治療膽管癌的候選藥物<ref name="PatelBorad2014">{{cite journal|last1=Patel|first1=Tushar|last2=Borad|first2=Mitesh|last3=Rizvi|first3=Sumera|last4=Gores|first4=Gregory|title=Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities|journal=Seminars in Liver Disease|volume=34|issue=04|year=2014|pages=456–464|issn=0272-8087|doi=10.1055/s-0034-1394144}}</ref>。[[光動力治療|光動力治療]]則是使用對特定光波長敏感的藥物的新型療法，[[隨機對照試驗|隨機對照試驗]]的結果顯示此療法對無法手術切除腫瘤的患者而言能有效提高存活率<ref name="ZoepfJakobs2005">{{cite journal|last1=Zoepf|first1=Thomas|last2=Jakobs|first2=Ralf|last3=Arnold|first3=Joachim C.|last4=Apel|first4=Darius|last5=Riemann|first5=Jurgen F.|title=Palliation of Nonresectable Bile Duct Cancer: Improved Survival After Photodynamic Therapy|url=https://archive.org/details/sim_american-journal-of-gastroenterology_2005-11_100_11/page/2426|journal=The American Journal of Gastroenterology|volume=100|issue=11|year=2005|pages=2426–2430|issn=0002-9270|doi=10.1111/j.1572-0241.2005.00318.x}}</ref><ref name="OrtnerCaca2003">{{cite journal|last1=Ortner|first1=Marianne E.J|last2=Caca|first2=Karel|last3=Berr|first3=Frieder|last4=Liebetruth|first4=Jochen|last5=Mansmann|first5=Ulrich|last6=Huster|first6=Dominik|last7=Voderholzer|first7=Winfried|last8=Schachschal|first8=Guido|last9=Mössner|first9=Joachim|last10=Lochs|first10=Herbert|title=Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study|url=https://archive.org/details/sim_gastroenterology_2003-11_125_5/page/1355|journal=Gastroenterology|volume=125|issue=5|year=2003|pages=1355–1363|issn=00165085|doi=10.1016/j.gastro.2003.07.015}}</ref>。另外，偵測腫瘤[[基質細胞|基質細胞]]副產物在血液中濃度的技術也正在發展，此方法可用於協助癌症診斷<ref>{{cite journal |vauthors=Alphonse ES, Gregory JG|title=Desmoplastic Stroma and Cholangiocarcinoma: Clinical Implications and Therapeutic Targeting |journal=Hepatology| volume=59 |issue=6 |pages=2397–2402 |year=2014 |pmid=|doi=10.1002/hep.26762}}</ref>。

== 參考資料 ==
{{reflist|2}}

==外部連結==
{{commons category}}
* [https://web.archive.org/web/20070310210114/http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=69 美國癌症協會對膽管癌的詳細指引] {{Language icon|en}}
* [[美國國家癌症中心|美國國家癌症中心]][http://www.cancer.gov/cancertopics/pdq/treatment/bileduct/Patient/ 給肝外膽管癌病患的相關資訊] {{Wayback|url=http://www.cancer.gov/cancertopics/pdq/treatment/bileduct/Patient/ |date=20150503153126 }} {{Language icon|en}}
* 美國國家癌症中心對[http://www.cancer.net/cancer-types/bile-duct-cancer/ 膽管癌的介紹] {{Wayback|url=http://www.cancer.net/cancer-types/bile-duct-cancer/ |date=20161021130906 }} {{Language icon|en}}
* [http://www.cholangiocarcinoma.org/ 膽管癌基金會] {{Wayback|url=http://www.cholangiocarcinoma.org/ |date=20210316072020 }}：提供膽管癌病患和其家屬、親友、照護者相關的資源。{{Language icon|en}}
* [http://www.ammf.org.uk Alan Morement 紀念基金會] {{Wayback|url=http://www.ammf.org.uk/ |date=20210331100049 }}：英國唯一致力於膽管癌的慈善團體。{{Language icon|en}}

{{模板:消化系統腫瘤}}
{{Authority control}}
[[Category:消化系统肿瘤|Category:消化系统肿瘤]]
[[Category:肝脏病学|Category:肝脏病学]]
[[Category:罕见癌症|Category:罕见癌症]]
[[Category:癌症|Category:癌症]]
{{Featured article}}